Blog

A DEA Order to Show Cause (OSC) can place a physician’s ability to prescribe controlled substances and in some cases their entire practice at risk. While many practitioners assume recordkeeping deficiencies are minor administrative issues, the DEA often views inconsistent drug administration logs and documentation errors as evidence that continued registration may be inconsistent with the public interest. As a result, recordkeeping violations can become the basis for suspension or revocation proceedings. In this Read more

St. Louis trial lawyer assumes leadership of premier international transportation bar association ST. LOUIS, MO (May 4, 2026) — Lashly & Baer, P.C. is pleased to announce that Patrick E. Foppe, a member of the firm and Co-Chair of its Litigation Group, has been elected President of the Transportation Lawyers Association (TLA), a premier international bar association serving attorneys who counsel motor carriers, freight forwarders, brokers, shippers, insurers, and other participants in the transportation Read more

Lashly & Baer is proud to share that attorney, Steven M. Wallace, has been appointed Secretary of the Illinois State Bar Association’s Commercial Banking, Collections & Bankruptcy Law Section Council for the 2026–2027 term. This appointment reflects Steve’s dedication to the legal profession and his continued commitment to serving both clients and the broader legal community. In this role, he will collaborate with fellow section members to support educational initiatives, contribute to thought leadership, Read more

When a physician withdraws a privileges application during FPPE… does it trigger NPDB reporting? It’s a question many hospitals wrestle with—and the answer isn’t always straightforward. In this article, healthcare attorney Michael Barth of Lashly & Bear, P.C. breaks down what organizations need to know. The key lies in how Focused Professional Practice Evaluation (FPPE) is defined: Is it a routine process applied to all applicants… or does it rise to the level of Read more

February, 2026: The use of telemedicine to prescribe controlled substances has seen a dramatic increase in recent years, accelerated by the COVID-19 pandemic and subsequent temporary flexibilities in regulations. On December 30, 2025, the U.S. Drug Enforcement Administration (DEA) and the Department of Health and Human Services published the fourth extension of a rule  “temporarily extended a rule allowing clinicians to prescribe controlled medications remotely through the end of 2065.” This extension, which took Read more